Site logo
Pharmaville Logo
    • Featured
    • Cornerstone Life Science Locations
    • Home
    • Locations
    • Events
    • Articles
      • Featured Editorial & Interviews
      • News and Insights
      • Xtalks Clinical Edge Magazine
    • More
      • Add or Update a Listing
      • About Pharmaville
      • Visit Xtalks
      • Contact
      • Terms of Use
      • Privacy Notice
    Add or Enhance a Listing
    Sign in or Register
    Add or Enhance a Listing
    Listing cover image

    Mexico

    • Claim listing
    • Location Details
    • Related Events
    • prev
    • next
    • Contact Us
    • Bookmark
    • Share
    • Claim listing
    • prev
    • next
    Description

    Mexico's life sciences ecosystem has evolved into a powerhouse of advanced manufacturing and biopharmaceutical innovation, serving as a critical hub for the North American market.

    Best known as a global leader in medical device manufacturing, the country hosts major clusters in Tijuana and Ciudad Juárez that export medtech ranging from specialized surgical instruments to high-tech diagnostic equipment.

    Under the USMCA trade agreement, Mexico offers a sophisticated regulatory environment and robust intellectual property protections, attracting significant Foreign Direct Investment (FDI) from multinational giants.

    The pharmaceutical sector is equally robust, driven by a strong presence of contract manufacturing organizations (CMOs) and a growing demand for generic and biosimilar medicines. In the realm of biotechnology, Mexico is emerging as a regional center for genomics, bioinformatics and regenerative medicine, supported by a steady pipeline of STEM graduates annually.

    Academic research in Mexico is increasingly commercialized through public-private partnerships, fostering a vibrant startup scene focused on healthcare innovation and digital health solutions.

    The country's strategic nearshoring advantages and competitive operational costs make it an ideal destination for companies seeking to de-risk their global supply chains. Furthermore, Mexico's clinical trial infrastructure is expanding, offering diverse patient populations and high-quality medical facilities for international clinical research.

    As the ecosystem transitions toward higher-value production, Mexico is solidifying its status as a premier life sciences investment destination and a cornerstone of the global healthcare economy.

    Featured Editorial
    featured editorial
    Claim Your Profile to Receive a 1500-word Editorial Article

    Pharmaville offers locations the opportunity to be featured in an in-depth interview that highlights their unique strengths and advantages. These interviews showcase areas such as research expertise, clinical trial capacity, manufacturing infrastructure, and investment opportunities, and are published directly on the Pharmaville platform. This helps regions share their story with a global life science audience and position themselves as leading destinations for innovation and growth.

    Regions
    • Mexico
    • North America
    Healthcare and Research Infrastructure

    Mexico's healthcare system is a hybrid public-private model, with the public system covering the majority of the population. An estimated 70% to 80% of medical services nationwide are delivered by public healthcare institutions, while private-sector providers serve roughly 25% to 30% of Mexicans. Public healthcare services in Mexico are delivered through three major institutions: the Mexican Institute of Social Security (Instituto Mexico de Seguro Social or IMSS), the Institute of Safety and Social Services for Public Sector Workers (Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado or ISSSTE) and the Secretary of Health (Secretaria de Salud or SSA). Total health expenditure was around $83.72 billion in 2022, representing approximately 6.2% of GDP. According to 2023 OECD data, Mexico spent $1,181 per capita on health, less than the OECD average of $4,986 (USD PPP or purchasing power parity). This is equal to 5.5% of GDP, compared to 9.2% on average in the OECD.

    Mexico's research ecosystem is still developing relative to top-tier global hubs. The country's main public R&D agency, Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT, formerly CONACYT), supports national science, technology and innovation programs. In 2023, federal R&D spending totaled around MXN 31 billion to 33 billion (USD $1.8 billion to $2.0 billion), equivalent to only about 0.3% of GDP.

    Mexico's biomedical research infrastructure is anchored by several national institutes, including: UNAM's National Autonomous University of Mexico, the country's leading research institution with extensive capabilities in biomedical sciences, chemistry, biotechnology, pharmacology and genomics; the National Institutes of Health of Mexico (INSalud) in Mexico City, comprised of 13 national institutes representing the country's most advanced hospital-based research network (e.g., INCMNSZ for nutrition, INCan for cancer, INER for respiratory diseases); Cinvestav (Center for Research and Advanced Studies), a major hub for biotechnology, nanoscience and biomedical engineering research; and the National Laboratory of Genomics for Biodiversity (LANGEBIO-CINVESTAV), a key player in genome analysis, plant/animal genomics and biotechnology. There are also regional clusters such as Guadalajara, Nuevo León (Monterrey), Querétaro and Puebla that feature biotech parks, medtech manufacturing and academic-industry collaborations.

    Gallery
    Government and Public Research Funding

    In contrast to the OECD average where the private sector leads innovation, public funding in Mexico accounts for approximately 75% to 80% of total R&D spending, with the federal government remaining the primary driver of scientific activity through agencies like CONAHCYT.

    Investment and Financing

    Mexico invests $2.5 billion to $3.0 billion annually in health-related R&D.

    Industry Presence

    The Mexican pharmaceutical industry is notable for hosting 20 of the world's 25 largest pharmaceutical companies. Major pharma companies with a presence in Mexico include Pfizer, Roche, Novartis, Sanofi, Janssen, AstraZeneca, Takeda, GSK, Bayer and Merck.

    Big Medtech Presence

    Mexico is a global leader in medtech manufacturing, with major facilities from Medtronic, BD, Johnson & Johnson, Stryker, Smith & Nephew and others. While the country imports nearly 90% of its medical devices, it is also a major exporter, particularly to the US. Mexico is the second largest medical device market in Latin America, following Brazil, and the leading medical importer in Latin America. Tijuana, located in Baja California, is a prominent medtech manufacturing hub in Mexico that has around 70 medical device manufacturing companies. The medtech industry in Baja California employs around 55,000 people. The country's medtech sector employs over 170,000 people in total. Mexico's digital health market is forecast to generate $2.31 billion in 2025, growing at a 5.04% CAGR to a projected market volume of $2.96 billion by 2030.

    Active Clinical Studies

    Mexico has over 1,000 active clinical studies.

    Location
    • Mexico City, Mexico

      Get Directions
    Related Events
    No Upcoming or Recorded Events Available
    Categories
    • Growth Life Science Locations
    Tags
    • Medtech Manufacturing
    Videos
    Listing image
    Economic Contribution

    In 2024, Mexico's pharmaceutical and health sectors contributed approximately 5.1% to the national GDP.

    Life Science Workforce

    Mexico's science and engineering workforce exceeds 1.5 million, with around 150,000 in biotech, chemical and biomedical roles. Medtech manufacturing employs more than 170,000 workers, particularly in Baja California, Chihuahua, Nuevo León and Jalisco.

    Laboratory and Manufacturing Space

    Mexico hosts more than 400 pharma manufacturing sites and over 600 medtech manufacturers, with a pharmaceutical market valued at $12 billion to $14 billion in 2024. By the end of 2025, Mexico will have added over 346,000 ft² of life sciences manufacturing space in Tijuana, 894,351 ft² in Hidalgo and 935,372 ft² in Queretaro.

    Talent, Innovation and IP

    Mexico invests around 0.3% of GDP in R&D, which is low even in comparison to Latin America overall, which only invests on average 0.62% of GDP in R&D, making it second lowest globally after sub-Sharan Africa.

    Website

    Claim Profile to Update Website

    Contact

    Claim Profile to Update Contact Information

    Links

    Claim Your Profile to Add Related Links

    Downloadables

    Claim Your Profile to add downloadable documentation

    References

    https://pharmaville.com/wp-content/uploads/2026/02/Pharmaville-Mexico-references.pdf

    Related Event
    No Upcoming or Recorded Events Available

    You May Also Be Interested In

    San Francisco, California Verified listing

    Featured
    • Biopharma Hub
    • Add to comparison

    Ontario

    • Regenerative Medicine & Cell Therapy
    • Add to comparison

    Newfoundland and Labrador

    • Population Genetics & Real-World Evidence
    • Add to comparison
    • Terms of Use
    • Privacy Notice

    © Honeycomb Worldwide Inc.

    Cart

      • Featured
      • Cornerstone Life Science Locations
      • Facebook
      • LinkedIn